Diagnostic assay for cancer

• US 6,194,158 B1
• Filed: 11/12/1999
• Issued: 02/27/2001
• Est. Priority Date: 11/12/1998
• Status: Expired due to Fees

• Current Assignee: Nyxis Neurotherapies, Inc. (Abbvie Incorporated)
• Original Assignee: Nyxis Neurotherapies, Inc. (Abbvie Incorporated)
• Inventors: Yamamoto, Hirotaka, Moskal, Joseph R., Kroes, Roger A.
• Primary Examiner(s): Fredman, Jeffrey
• Assistant Examiner(s): CHAKRABARTI, ARUN K
• Application Number:
  US09/438,938
• Time in Patent Office: 473 Days
• Field of Search: 435/6, 435/91.2, 435/91.4, 536/22.1, 536/23.1
• US Class Current: 435/6.16
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 1/6897 involving reporter genes operably linked to promoters
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds

Abstract

The invention is directed towards gene expression characteristic for cancer, in particular brain cancers such as glioblastoma. Compositions, methods and kits encompassing such therein.

Claims

1. A method for ascertaining the propensity of a cell for malignant phenotype, said cell being isolated or in a biological sample, said method comprising assaying the cell or biological sample for a signal indicating the transcription of a nucleic acid transcript, said transcript corresponding to at least one nucleic acid sequence selected from the group consisting of CINN 1 (SEQ ID NO.:

8), OP11 C1-3 (SEQ ID NO.;

     4), FAS OP17 (SEQ ID NO.;

     7).

2. The method of claim 1, wherein said transcript is detected by RT-PCR using at least one amplification primer corresponding to at least one of OP11 C1-3 (SEQ ID NO.:

4), FAS OP17 (SEQ ID NO.;

     7), CINN 1 (SEQ ID NO.;

     8).

3. The method of claim 1, wherein said transcript is detected by nucleic acid hybridization using at least one nucleic acid probe corresponding to at least one of OP11 C1-3 (SEQ ID NO.:

4), FAS OP17 (SEQ ID NO.;

     7), or CINN 1 (SEQ ID NO.;

     8).

4. The method of claim 3, wherein said assay is in situ hybridization.

5. The method of claim 1, wherein said transcript is detected by RNase protection assay.

6. A method for ascertaining the suitability of an anti-neoplastic drug candidate for efficacy in treating a malignancy, wherein said method comprises combining said candidate drug with a cell having a cancer phenotype, said cell being isolated or in a biological sample, detecting in said cell or biological sample any change in the expression of at least one nucleic acid sequence corresponding to at least one of OP11 C1-3 (SEQ ID NO.:

4), FAS OP17 (SEQ ID NO;

     7), or CINN 1 (SEQ ID NO.;

     8).

7. A method as in claim 6, wherein said malignant biological sample is a biopsy sample from a patient to be treated.

8. A method as in claim 6, wherein said malignant biological sample is a cell line.

9. A method as in claim 6, wherein said malignant biological sample is a cell.

10. A method for ascertaining the propensity of a cell for malignant phenotype, said cell being isolated or in a biological sample, said method comprising assaying the cell or biological sample for a signal indicating the transcription of at least a first and a second nucleic acid transcript, said first transcript corresponding to at least one nucleic acid sequence selected from the group consisting of OP11 C1-3 (SEQ ID NO.:

4), FAS OP17 (SEQ ID NO.;

     7), and CINN 1 (SEQ ID NO.;

     8), said second transcript corresponding to at least one nucleic acid sequence selected from the group consisting of OP2 C2-6 (SEQ ID NO.

     1), OP7 C3-1 (SEQ ID NO.;

     2), OP9 A4-2 (SEQ ID NO.;

     3), OP11 G2-10 (SEQ ID NO.

     5), FAS OP13 (SEQ ID NO.

     6), and CINN 2 (SEQ ID NO.

     9).

11. The method of claim 10, wherein said signal is detected by RT-PCR, said first transcript being amplified using at least one amplification primer corresponding to OP11 C1-3 (SEQ ID NO.:

4), FAS OP17 (SEQ ID NO.;

     7), or CINN 1 (SEQ ID NO.;

     8) said second signal being amplified using at least one amplification primer corresponding to OP2 C2-6 (SEQ ID NO.

     1), OP7 C3-1 (SEQ ID NO.;

     2), OP9 A4-2 (SEQ ID NO.;

     3), OP11 G2-10 (SEQ ID NO.

     5), FAS OP13 (SEQ ID NO.

     6), or CINN 2 (SEQ ID NO.

     9).

12. The method of claim 10, wherein said first and second transcripts are detected by nucleic acid hybridization, said first transcript being detected using at least one nucleic acid probe corresponding to OP11 C1-3 (SEQ ID NO.:

4), FAS OP17 C1-D (SEQ ID NO.;

     7), or CINN 1 (SEQ ID NO.;

     8), said second transcript being detected using at least one nucleic acid probe corresponding to OP2 C2-6 (SEQ ID NO.

     1), OP7 C3-1 (SEQ ID NO.;

     2), OP9 A4-2 (SEQ ID NO.;

     3), OP11 G2-10 (SEQ ID NO.

     5), FAS OP13 (SEQ ID NO.

     6), or CINN 2 (SEQ ID NO.

     9).

13. The method of claim 12, wherein said assay is in situ hybridization.

14. The method of claim 10, wherein said transcript is detected by RNase protection assay.

15. A method for ascertaining the suitability of an anti-neoplastic drug candidate for efficacy in treating a malignancy, wherein said method comprises combining said candidate drug with a cell having a cancer phenotype, said cell being isolated or in a biological sample, detecting in said cell or biological sample any change in the expression of at least a first and a second nucleic acid transcript, sad first transcript corresponding to at least one nucleic acid sequence selected from the group consisting of OP11 C1-3 (SEQ ID NO.:

4), FAS OP17 (SEQ ID NO.;

     7), and CINN 1 (SEQ ID NO.;

     8), said second transcript corresponding to at least one nucleic acid sequence selected from the group consisting of OP2 C2-6 (SEQ ID NO.

     1), OP7 C3-1 (SEQ ID NO.;

     2), OP9 A4-2 (SEQ ID NO.;

     3), OP11 G2-10 (SEQ ID NO.

     5), FAS OP13 (SEQ ID NO.

     6), and CINN 2 (SEQ ID NO.

     9).

16. A method as in claim 15, wherein said malignant biological sample is a biopsy sample from a patient to be treated.

17. A method as in claim 15, wherein said malignant biological sample is a cell line.

18. A method as in claim 15, wherein said malignant biological sample is a cell.